Cancer Network Staff

Results from a phase 1/2a trial and the ongoing FORTE basket study support the FDA’s regulatory decision for these patients with recurrent or progressive glioma.

The phase 3 EMERALD-3 trial met its primary end point of PFS with durvalumab, tremelimumab, lenvatinib, and TACE in patients with unresectable HCC.

Management strategies for oxybutynin-induced xerostomia include hydration, sugar-free gum, and humidification.

BiliSeqV2/V3 improved neoplastic bile duct stricture identification compared with pathology alone, according to a study from UPMC investigators.

Results from the phase 1/2 ReFocus trial demonstrated positive activity from lirafugratinib in the various pretreated, FGFR2-mutated cholangiocarcinoma populations.

ZW191 is currently under evaluation in a phase 1 trial that has already demonstrated activity among patients with platinum-resistant ovarian cancer.

Linda Carlson, PhD, RPsych, explored the shift from efficacy to implementation in integrative oncology, emphasizing behavioral interventions.

Adding atezolizumab to adjuvant FOLFOX significantly improves disease-free survival for patients with stage III mismatch repair-deficient colon cancer.

Updated data demonstrated a 14.7-month OS benefit when adding IMNN-001 to neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.

Rahul Aggarwal, MD, discussed the high unmet needs of neuroendocrine prostate cancer, highlighting biopsy triggers, genomic markers, and emerging targets.

ECG changes and cardiac biomarkers were evaluated in patients with breast cancer to identify early markers of chemotherapy-induced cardiotoxicity.

The FDA has cleared an investigator-initiated investigational new drug application for a first-in-class AAV immuno-gene therapy in recurrent high-grade glioma.

Germline platelet polygenic risk score predicted a 37% higher risk of death in patients with renal cell carcinoma, mediated by sustained thrombocytosis.

Three Neuroendocrine Tumor Research Foundation grant winners outlined research that aimed to deliver biology-driven strategies to patients.

FG001 is an investigational uPAR-targeting fluorophore designed to provide real-time illumination of aggressive brain tumors during surgical resection.

Sacituzumab govitecan and pembrolizumab were recommended as category 1 regimens for metastatic triple-negative breast cancers based on 2 phase 3 trials.

The irinotecan-based ChemoSeed delivery mechanism is currently under investigation for patients with malignant glioma in a registrational phase 2 trial.

Julian Hong, MD, MS, discussed an analysis showing that patients with cancer and new mental health disorders have an increased risk of all-cause mortality.

Results from a phase 1b trial for givastomig in frontline HER2-negative, PD-L1–positive gastroesophageal cancer support the FDA’s decision.

Emergent phase 1 LuPARP study data suggest that metastatic castration-resistant prostate cancer could be treated with PARP inhibition and radionuclides.

The updated NDA submitted to the FDA included additional data and statistical analyses from existing clinical trials for pediatric and adult patients with glioma.

Lynette Fernandez-Cuesta, PhD, discussed how the Petersen Accelerator Grant will drive the development of real-time clinical biomarkers for aggressive lung NETs.

The addition of SBRT to an immunotherapy doublet did not significantly affect safety outcomes among patients with de novo metastatic RCC.

Integrating a medically supervised ketogenic diet with gemcitabine, nab-paclitaxel, and cisplatin significantly extends OS in those with metastatic PDAC.

Key takeaways from the 43rd Miami Breast Cancer Conference focused on managing oligometastatic and oligoprogressive breast cancer with metastasis-directed therapy.

Zolucatetide yielded a DCR of 100% and ORR of 80% among patients with secretase-naive and secretase-treated desmoid tumors.

DecisionDx-Melanoma’s i31-SLNB accurately predicted low nodal positivity and high recurrence-free survival in patients with cutaneous melanoma.

Tousimis explored the feasibility, complications, and surgical strategies for nipple-sparing mastectomy in patients with a history of radiation therapy.

Sebnem Ece Eksi, PhD, discussed how sympathetic signaling drives CAF activation and tissue remodeling to support tumor progression in pancreatic cancer.

Denileukin diftitox plus pembrolizumab achieved an ORR of 24% among patients with relapsed or refractory gynecologic cancers.